In murine models of T2DM and obesity, GLP-1-Fc-FGF21 D1 improved liver function, serum and hepatic lipid profiles, and reduced body weight and NAS scores with an efficacy superior to either FGF21 or GLP1R agonists alone [75]. This evidence concerns the gene FGF21 and obesity disorder.